St Jude Medical Inc (STJ) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
290 |
Employees |
16,000 |
Revenues (TTM) (Millions $) |
5,956 |
Net Income (TTM) (Millions $) |
658 |
Cash Flow (TTM) (Millions $) |
-512 |
Capital Exp. (TTM) (Millions $) |
220 |
St Jude Medical Inc
St. Jude Medical Inc. is a global medical device company that develops and manufactures health products for patients with heart disease, neurological disorders, chronic pain, and other medical conditions. The company was founded in 1976 in St. Paul, Minnesota, and has since expanded to become a world leader in medical technology.
The company offers a diverse range of innovative products including pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, heart valves, and peripheral vascular products. These products are designed to address a variety of cardiac and neurological conditions such as arrhythmias, heart failure, Parkinson's disease, essential tremor, and chronic pain.
St. Jude Medical has a commitment to innovation and research and development, investing heavily in cutting-edge technology to advance the field of medical devices. The company's research and development efforts have led to significant breakthroughs in cardiac and neurological health, including the development of advanced algorithms for pacemaker programming and the introduction of MRI-safe cardiac devices.
St. Jude Medical has established a strong global presence, operating in over 100 countries worldwide. The company employs more than 16,000 people and has manufacturing facilities in the United States, Asia, Europe, and Latin America.
In addition to its product offerings, St. Jude Medical is also known for its commitment to patient care and support. The company provides educational resources and tools for patients and healthcare professionals, offering a range of services to help patients manage their conditions and improve their quality of life.
Over the years, St. Jude Medical has received numerous awards and recognitions for its contributions to medical technology and patient care. The company's dedication to innovation and commitment to improving patient outcomes make it a leading force in the medical device industry.
|
|
Customers Net Income fell by |
STJ's Customers Net Profit Margin grew to |
-31.37 % |
2.53 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Co Diagnostics Inc
Co Diagnostics Inc Announces Strong Revenue Growth and Declining Inventories Salt Lake City, March 14, 2024 - Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has reported its financial results for the full year ended December 31, 2023. The company's revenue for the fourth quarter of 2023 showed a remarkable growth of 140.476% year on year, amounting to $3.37 million. However, they experienced a loss of $-0.50 per share during this period. In comparison to other companies in the Medical Equipment and Supplies sector, Co Diagnostics Inc exhibited higher revenue growth. While the overall sector saw a revenue growth of 6.78% in the fourth quarter of 2023 relative to the same period a year ago, Co Diagnostics Inc surpassed this with its substantial increase.
|
Nephros Inc
As a Wall Street journalist, it is important to analyze the financial performance of companies like Nephros Inc in order to provide valuable insights to investors. For the fiscal fourth quarter of 2023, Nephros Inc reported a loss of $0.06 per share, which was an improvement from the loss of $0.16 per share in the same period a year prior. However, compared to the previous financial reporting period, the company's loss per share increased from $0.02. Despite the mixed results in terms of earnings, Nephros Inc saw a significant increase in revenue, with a growth rate of 67.971% to $3.44 million from $2.05 million in the same period last year. The company also reported a net loss of $0.654 million for the fiscal fourth quarter of 2023, compared to a loss of $1.527 million in the same period a year ago. While Nephros Inc's stockpiles increased to $2.5 million, it is worth noting that this level remains below the previous year's level of $3.2 million. The build-up in accounts receivable is a positive sign of rising demand, with accounts receivable valued at $1.5 million, higher than in the preceding quarter. Looking at the full-year results for 2023, Nephros Inc reported revenue of $13.41 million and a net loss of $1.58 million. The company managed to decrease its loss per share to $0.15 from $0.73 in the previous fiscal year, while revenue surged by 34.39% from $9.98 million a year prior.
|
Non Invasive Monitoring Systems Inc
The Medical Equipment and Supplies sector has been closely monitoring the performance of Non Invasive Monitoring Systems Inc as it enters the second quarter of 2024. The company has reported an operating loss of $-0.04 million for the period of November to January 31, 2024, with no mention of revenue figures thus far. This lack of revenue has raised concerns among sector contributors who are looking for signs of growth and financial stability. The Chief Financial Officer of Non Invasive Monitoring Systems Inc is actively pursuing various business strategies in an effort to expand the company's product line and increase profitability. However, the company continues to struggle, reporting a net loss of $-0.054 million for the same period. This represents an increase from the net loss of $-0.048 million reported during the similar period a year ago.
|
Anika Therapeutics Inc
In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price. Financial Performance Overview: During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $43.25 million, representing a growth of 9.151% year-on-year. In comparison to its contemporaries in the Medical Equipment and Supplies sector, Anika Therapeutics Inc.'s top-line growth outpaced the industry average, highlighting its strong market position.
|
Cytosorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies, has reported its financial performance for the fiscal period between October and December 31, 2023. While the company faced some challenges during this period, it also made significant progress and achieved notable accomplishments in the medical equipment and supplies sector. Financial Performance Summary During the mentioned fiscal span, Cytosorbents Corporation experienced a widening of diminishing returns, with a decrease of $0.12 per share compared to $0.02 a year ago. However, the company managed to improve its EPS from -$0.21 per share in the previous reporting season. Revenue declined by 15.714% to $7.91 million from $9.39 million in the same reporting season a year ago. Sequentially, revenue also deteriorated by 8.04% from $8.61 million.
|
Per Share |
Current |
Earnings (TTM) |
2.28 $ |
Revenues (TTM) |
20.54 $
|
Cash Flow (TTM) |
- |
Cash |
1.37 $
|
Book Value |
14.76 $
|
Dividend (TTM) |
1.22 $ |
|
Per Share |
|
Earnings (TTM) |
2.28 $
|
Revenues (TTM) |
20.54 $ |
Cash Flow (TTM) |
- |
Cash |
1.37 $
|
Book Value |
14.76 $ |
Dividend (TTM) |
1.22 $ |
|
|
|
ICD systems |
|
Segment |
|
|
of total Revenue |
Pacemaker systems |
|
Segment |
|
|
of total Revenue |
Cardiac rhythm management |
|
Segment |
|
|
of total Revenue |
Heart valves |
|
Segment |
|
|
of total Revenue |
Cardiac surgery |
|
Segment |
|
|
of total Revenue |
Vascular closure devices |
|
Segment |
|
|
of total Revenue |
Cardiology & vascular access |
|
Segment |
|
|
of total Revenue |
Atrial fibrillation |
|
Segment |
|
|
of total Revenue |
Neuromodulation products |
|
Segment |
|
|
of total Revenue |
|
|
|